The ESR1 mutated metastatic breast cancer diagnostics market is valued at USD 64.61 million in 2025 and is slated to reach USD 92.92 million by 2035, registering a compound annual growth rate (CAGR) of 3.7%. This growth is driven by the increasing prevalence of ESR1 mutations in metastatic breast cancer patients and the rising demand …